This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

First Effective Treatment For Traumatic Brain Injury Reported By Institute Of Neurological Recovery, Even Years After Injury

LOS ANGELES, Nov. 14, 2012 /PRNewswire/ -- The first treatment breakthrough of its kind for survivors of traumatic brain injury (TBI) or stroke will be published in the December 1 issue of the journal CNS Drugs[1], with an accompanying editorial[2].

To view the multimedia assets associated with this release, please click

The ground-breaking study provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumatic brain injury can rapidly improve following a single dose of a drug that targets brain inflammation, even years after the initial event. There are 5 million people living in the U.S. after TBI and 4.5 million living in the U.S. after stroke, and this is the first treatment of its kind ever available for TBI or stroke survivors after hospital discharge.

The observational study[1] of 629 patients, conducted over the course of nearly two years, documents a diverse range of positive effects, including statistically significant rapid clinical improvement in motor impairment, spasticity, cognition, etc. in the stroke group, with a similar pattern of improvement seen in the traumatic brain injury (TBI) group. The study involved 617 patients treated an average of 42 months after stroke and 12 patients treated an average of 115 months after TBI, long after further spontaneous meaningful recovery would be expected. The study was conducted at the Institute of Neurological Recovery utilizing a novel drug delivery method, invented by Edward Tobinick M.D., lead author of the study.

"These results represent a sea change in the therapeutic possibilities for stroke and TBI patients," said Steven Ralph PhD, Associate Professor at Griffith University School of Medical Science in Australia. Professor Ralph recently led a team of physicians to the INR for training in the new treatment method. "Our team observed, first hand, rapid clinical improvement in patients following this brief office treatment. Rarely do we see such a radical breakthrough in medical treatment as this. A previous example was the advance with thrombolytic therapy for acute stroke. However, no similar treatment has existed for this type of chronic brain dysfunction until now," said Professor Ralph.

The study's significance is underlined by average age of the TBI population, many of whom have been injured as teen-agers.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs